Lumos Pharma (NASDAQ:LUMO – Get Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, May 10th. Analysts expect the company to announce earnings of ($0.92) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Lumos Pharma (NASDAQ:LUMO – Get Rating) last announced its quarterly earnings results on Thursday, March 10th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.24. The firm had revenue of $0.22 million during the quarter. On average, analysts expect Lumos Pharma to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Shares of LUMO stock opened at $8.52 on Tuesday. Lumos Pharma has a fifty-two week low of $6.15 and a fifty-two week high of $12.38. The firm has a fifty day moving average price of $9.18.
Separately, Zacks Investment Research cut Lumos Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 5th.
Lumos Pharma Company Profile (Get Rating)
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.
- Get a free copy of the StockNews.com research report on Lumos Pharma (LUMO)
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- GitLab Stock is Trying to Put in a Bottom Here
- Saia Growth Accelerates But It May Not Matter
- It’s Time to Book an Appointment for Teladoc Stock
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.